Does Cosentyx List Liver Damage as a Side Effect?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not commonly cause liver damage. Clinical trials and post-marketing data show no direct link to hepatotoxicity in product labeling or major studies. Liver enzyme elevations (ALT/AST) occur in under 5% of patients, typically mild and transient, resolving without stopping treatment.[1][2]
What Do Clinical Trial Data Show on Liver Safety?
In pivotal trials like FUTURE and MEASURE, serious liver events were rare (0.1-0.5% incidence), often tied to comorbidities or concurrent meds rather than Cosentyx. No cases of drug-induced liver injury (DILI) were causally attributed. Long-term extensions up to 5 years confirm low hepatotoxicity risk.[3]
Are There Real-World Reports or Case Studies?
Post-approval surveillance via FDA FAERS database logs isolated ALT/AST spikes, but causality is unproven—many involve alcohol use, infections, or other drugs like methotrexate. No confirmed fatal liver failures linked solely to Cosentyx. European Medicines Agency reviews echo this, rating liver risk as "not established."[4][5]
Who Might Face Higher Liver Risks?
Patients with baseline liver disease, heavy alcohol use, or combo therapy (e.g., with NSAIDs/steroids) see slightly higher enzyme elevations (up to 10%). Monitoring guidelines recommend baseline and periodic LFTs every 3-6 months in at-risk groups, per prescribing info.[1]
How Does Cosentyx Compare to Other Biologics on Liver Impact?
Unlike TNF inhibitors (e.g., Humira, with 1-2% moderate hepatotoxicity), Cosentyx has a cleaner liver profile due to its targeted IL-17 mechanism, avoiding broad immune suppression. Methotrexate, often used pre-biologic, carries far higher DILI risk (15-20%).[6]
What Should Patients Do if Concerned About Liver Issues?
Report symptoms like jaundice, fatigue, or abdominal pain to a doctor immediately. Routine bloodwork catches issues early; discontinuation rarely needed. No black-box liver warning exists.[1]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: Drugs.com - Cosentyx Side Effects
[3]: NEJM - Secukinumab Phase 3 Trials
[4]: FDA FAERS Public Dashboard
[5]: EMA Cosentyx Assessment Report
[6]: DrugPatentWatch.com - Secukinumab Patent Landscape